Data for Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver (Study ST000915)
(Analysis AN001487)Values for each metabolite have been scaled by dividing by the mean across all factors Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study| Metabolite | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| CL (70:7) | 0.9468 | 1.0769 | 1.0363 | 0.9059 |
| CL (72:8) | 0.6901 | 0.9958 | 1.1167 | 1.1569 |
| CL (74:7) | 0.5805 | 1.0548 | 1.1802 | 1.1005 |
| CL (74:8) | 0.6713 | 1.0709 | 1.1813 | 0.9726 |
| CoQ-10 | 1.1236 | 0.7953 | 1.1397 | 0.8407 |
| CoQ-9 | 1.0084 | 1.0631 | 1.0574 | 0.8111 |
| Dolichol-17 | 0.4966 | 0.9806 | 1.2925 | 1.0990 |
| Dolichol-18 | 0.5378 | 0.9727 | 1.2676 | 1.1036 |
| Dolichol-19 | 0.4610 | 0.9999 | 1.2882 | 1.1255 |
| Dolichol-20 | 0.3821 | 1.0242 | 1.2912 | 1.1847 |
Factors:
| F1 | Diagnosis:Cirrhosis |
| F2 | Diagnosis:NASH |
| F3 | Diagnosis:Normal |
| F4 | Diagnosis:Steatosis |
